231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Oncology"
DOI: 10.1016/j.annonc.2020.10.451
Abstract: s Annals of Oncology progression and how it would impact their family and lives, the impact that mCRPC has on their daily, physical abilities (e.g. difficulty walking, muscle loss) and the impact a patients’ mCRPC… read more here.
Keywords: expert testimony; bureau expert; speaker bureau;
Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz246.100
Abstract: Abstract Background In metastatic colorectal cancer (mCRC), circulating tumour DNA (ctDNA) monitoring can be used to genotype tumors and track clonal evolution. We investigated the clearance of RAS mutated clones under chemotherapy pressure by ctDNA… read more here.
Keywords: consultancy speaker; expert testimony; speaker bureau; advisory consultancy ... See more keywords
A phase I study of HMPL-689, a selective oral phosphoinositide 3-kinase-delta inhibitor, in patients with relapsed or refractory lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz251.041
Abstract: Abstract Background The B-cell receptor (BCR) signaling pathway plays a central role in non-Hodgkin lymphoma (NHL). Despite available agents targeting the BCR pathway, there continues to be a need for alternative therapies in the relapsed/refractory… read more here.
Keywords: expert testimony; speaker bureau; advisory consultancy; bureau expert ... See more keywords
Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz258.010
Abstract: Abstract Background Data on the frequency of EGFR mutations in patients (pts) with NSCLC potentially eligible for adjuvant therapy are limited. Osimertinib, a 3rd-generation, irreversible, oral EGFR-tyrosine kinase inhibitor (TKI), potently and selectively inhibits both… read more here.
Keywords: expert testimony; speaker bureau; advisory consultancy; bureau expert ... See more keywords
The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz260.042
Abstract: Abstract Background Pembrolizumab (Pem) for NSCLC and PD-L1 TPS ≥50% as a first-line therapy showed the longer PFS and OS compared with chemotherapy in some clinical trial. However, only limited patients in good general condition… read more here.
Keywords: bureau expert; expert testimony; speaker bureau;
Durvalumab plus tremelimumab for the treatment of patients (pts) with refractory and progressive advanced thyroid carcinoma: A phase II multicohort trial (DUTHY / GETNE T1812)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz267.009
Abstract: Abstract Background Preliminary studies have suggested that the activity of anti-PD-1 immune check-point inhibitors in thyroid cancer is low. However, we hypothesize that combining CTLA-4 and PD-L1 clockade could have a higher effet in the… read more here.
Keywords: expert testimony; speaker bureau; cohort; advisory consultancy ... See more keywords
Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz437.040
Abstract: Abstract Background Polypharmacy (PP) is a common problem in elderly patient population. However, the prevalence and impact of PP on treatment-related morbidities in elderly patients with advanced cancer have not been well investigated. Methods We… read more here.
Keywords: expert testimony; speaker bureau; elderly patients; cancer ... See more keywords
Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz447
Abstract: Abstract Background TMB is a novel predictive biomarker that can identify patients who may benefit from immunotherapy. NSCLC trial data suggest that whole exome sequencing (WES) and panel-sequencing are suitable to determine TMB, and that… read more here.
Keywords: panel; bureau expert; expert testimony; speaker bureau ... See more keywords
Immune checkpoint inhibitors (ICI) in combination with chemotherapy as first-line (1L) treatment for non-small cell lung cancer (NSCLC): A pair-wise meta-analysis (MA)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz451.025
Abstract: Abstract Background ICI has revolutionized the treatment of lung cancer, with new approaches in 1L NSCLC. The aim of this study is to compare the efficacy of treatments that combine chemotherapy (CH) plus a PD1/L1… read more here.
Keywords: expert testimony; speaker bureau; advisory consultancy; bureau expert ... See more keywords
1066. Immune Escape Mutant Detection Using Commercially Available Methods for Hepatitis B Surface Antigen Serological Testing
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1252
Abstract: Although overall infection rates of Hepatitis B virus (HBV) in the United States (US) remain stable, as many as 2.2 million persons are still chronically infected with Hepatitis B Virus (HBV)1. Persons who inject drugs… read more here.
Keywords: panel; hbsag; consultant; speaker bureau ... See more keywords
1327. Vancomycin Dosing by AUC24/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
Sign Up to like & getrecommendations! Published in 2020 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofaa439.1509
Abstract: New vancomycin (VAN) guidelines have been published, with recommendations that dosing in patients (pts) with methicillin-resistant S. aureus (MRSA) infections be guided by VAN area under the concentration-time curve from 0 to 24 h to… read more here.
Keywords: vancomycin; trough levels; auc24; speaker bureau ... See more keywords